CA2448746A1 - Methods and compositions useful for the prediction of blood-brain barrier permeation - Google Patents
Methods and compositions useful for the prediction of blood-brain barrier permeation Download PDFInfo
- Publication number
- CA2448746A1 CA2448746A1 CA002448746A CA2448746A CA2448746A1 CA 2448746 A1 CA2448746 A1 CA 2448746A1 CA 002448746 A CA002448746 A CA 002448746A CA 2448746 A CA2448746 A CA 2448746A CA 2448746 A1 CA2448746 A1 CA 2448746A1
- Authority
- CA
- Canada
- Prior art keywords
- mixture
- brain
- polar lipid
- membrane
- dodecane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
The present invention provides a method for the in vitro determination of the ability of a compound or a mixture of compounds to permeate the blood-brain barrier and a membrane composition useful therefor.
Description
METHODS AND COMPOSITIONS USEFUL FOR THE PREDICTION OF
BLOOD-BRAIN BARRIER PERMEATION
This invention relates to methods for predicting the ability of compounds to cross the blood-brain barrier, and to membrane compositions for use in such methods.
BACKGROUND OF THE INVENTION
To be effective as therapeutic agents, centrally acting pharmaceuticals must cross the blood-brain barrier (BBB). Conversely, to be devoid of unwanted central nervous system (CNS) effects, peripherally acting pharmaceuticals should demonstrate limited ability to cross the BBB. In either case, the BBB permeability of a pharmaceutical candidate needs to be known. However, the experimental determination of blood-brain partitioning is difficult, time-consuming, costly and unsuitable for screening large collections of chemicals. A broadly applicable method for predicting the BBB permeation of pharmaceutical candidates at an early stage of discovery would have a significant impact in pharmaceutical research and development. Methods which produce reliably predictable data related to BBB permeation for large numbers of compounds at an early stage of the discovery/development process are urgently needed.
Therefore, it is an object of this invention to provide a robust, efficient and predictive method for the in vitro determination of the BBB permeation capabilities of a test compound such as a potential pharmaceutical agent.
It is another object of this invention to provide a membrane composition useful for the in vitro determination of the BBB permeation capabilities of a test compound.
It is a feature of this invention that the BBB
permeation determinative method and composition provide high predictive value and high throughput efficiency.
It is another feature of this invention that said method and composition are adaptable to standard laboratory robotics platforms.
These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.
SUN~J'ARY OF THE INVENTION
The present invention provides a method for the determination of the ability of a compound or mixture of compounds to permeate the blood-brain barrier which comprises measuring the rate said compound or mixture of compounds passively diffuses through a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
The present invention further provides a membrane composition which comprises a porous solid support impregnated with a mixture of brain polar lipid extract and dodecane.
DETAILED DESCRIPTION OF THE INVENTION
Methods which can deliver reliable and predictive data related to blood-brain barrier (BBB) permeation for large numbers of compounds, i.e, 500-1,000 per day, at an early stage of the discovery development process would allow the rapid and inexpensive selection and optimization of pharmaceutical candidates for desirable brain penetration characteristics and may help in the differentiation between active, paracellular and transcellular processes. Known methods for predicting BBB penetration include computational methods using mathematical tools, cell culture methods using endothelial cell cultures from animal origin, high performance liquid chromotography (HPLC) using immobilized. artificial membrane columns, measurement of surface activity using critical micelle concentration methodology, microdialysis techniques involving sampling tissue from the brain of a living animal for external HPLC analysis, the use of postmortem human brain capillaries, and in vivo animal studies. None of these known methods are entirely suitable for obtaining economic, reliable and highly predictive BBB permeation data for large numbers of test compounds.
Surprisingly, it has now been found that the ability of a compound or a mixture of Compounds to permeate the blood-brain barrier may be determined in a highly predictive, reproducible, reliable, efficient and economic manner in vitro by measuring the rate said compound or mixture of compounds passively diffuses through a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
Advantageously, the method of the invention is suitable for use with standard laboratory robotics platforms.
The term passive diffusion, as used in the specification and claims, designates a process of transfer of individual molecules of a compound or mixture of compounds across a semi-permeable membrane which is brought about by random molecular motion and associated with a concentration gradient. The modifier passive refers both to the absence of external forces such as increased pressure, reduced pressure, gravity or the like and to the lack of active processes such as metabolism, the use of transporters or the like.
BLOOD-BRAIN BARRIER PERMEATION
This invention relates to methods for predicting the ability of compounds to cross the blood-brain barrier, and to membrane compositions for use in such methods.
BACKGROUND OF THE INVENTION
To be effective as therapeutic agents, centrally acting pharmaceuticals must cross the blood-brain barrier (BBB). Conversely, to be devoid of unwanted central nervous system (CNS) effects, peripherally acting pharmaceuticals should demonstrate limited ability to cross the BBB. In either case, the BBB permeability of a pharmaceutical candidate needs to be known. However, the experimental determination of blood-brain partitioning is difficult, time-consuming, costly and unsuitable for screening large collections of chemicals. A broadly applicable method for predicting the BBB permeation of pharmaceutical candidates at an early stage of discovery would have a significant impact in pharmaceutical research and development. Methods which produce reliably predictable data related to BBB permeation for large numbers of compounds at an early stage of the discovery/development process are urgently needed.
Therefore, it is an object of this invention to provide a robust, efficient and predictive method for the in vitro determination of the BBB permeation capabilities of a test compound such as a potential pharmaceutical agent.
It is another object of this invention to provide a membrane composition useful for the in vitro determination of the BBB permeation capabilities of a test compound.
It is a feature of this invention that the BBB
permeation determinative method and composition provide high predictive value and high throughput efficiency.
It is another feature of this invention that said method and composition are adaptable to standard laboratory robotics platforms.
These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.
SUN~J'ARY OF THE INVENTION
The present invention provides a method for the determination of the ability of a compound or mixture of compounds to permeate the blood-brain barrier which comprises measuring the rate said compound or mixture of compounds passively diffuses through a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
The present invention further provides a membrane composition which comprises a porous solid support impregnated with a mixture of brain polar lipid extract and dodecane.
DETAILED DESCRIPTION OF THE INVENTION
Methods which can deliver reliable and predictive data related to blood-brain barrier (BBB) permeation for large numbers of compounds, i.e, 500-1,000 per day, at an early stage of the discovery development process would allow the rapid and inexpensive selection and optimization of pharmaceutical candidates for desirable brain penetration characteristics and may help in the differentiation between active, paracellular and transcellular processes. Known methods for predicting BBB penetration include computational methods using mathematical tools, cell culture methods using endothelial cell cultures from animal origin, high performance liquid chromotography (HPLC) using immobilized. artificial membrane columns, measurement of surface activity using critical micelle concentration methodology, microdialysis techniques involving sampling tissue from the brain of a living animal for external HPLC analysis, the use of postmortem human brain capillaries, and in vivo animal studies. None of these known methods are entirely suitable for obtaining economic, reliable and highly predictive BBB permeation data for large numbers of test compounds.
Surprisingly, it has now been found that the ability of a compound or a mixture of Compounds to permeate the blood-brain barrier may be determined in a highly predictive, reproducible, reliable, efficient and economic manner in vitro by measuring the rate said compound or mixture of compounds passively diffuses through a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
Advantageously, the method of the invention is suitable for use with standard laboratory robotics platforms.
The term passive diffusion, as used in the specification and claims, designates a process of transfer of individual molecules of a compound or mixture of compounds across a semi-permeable membrane which is brought about by random molecular motion and associated with a concentration gradient. The modifier passive refers both to the absence of external forces such as increased pressure, reduced pressure, gravity or the like and to the lack of active processes such as metabolism, the use of transporters or the like.
The inventive method is a simple, high through-put physico-chemical method which uses a very small amount of sample, generally less than 0.1 mg, to accurately predict the ability of said sample to permeate the blood-brain barrier. In actual practice, a solution of known concentration of a compound or mixture of compounds in a buffer solution is separated from a buffer solution containing 0% concentration of said compound or mixture of compounds by a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane in such a way that the surface of each buffer solution is in contact with opposite sides of said impregnated membrane.
After a measured period of time, the concentration of said compound or mixture of compounds is determined for each buffer solution and the rate of diffusion is calculated.
In one embodiment of the invention, a 96-well plate filled with solutions of a known concentration of test sample in a buffer solution (donor) may be covered with a 96-well filter plate wherein the porous filter membrane is impregnated with a mixture of brain polar lipid extract and dodecane and the wells are filled with a buffer solution containing 0% concentration of test sample (acceptor) such that the surface of each buffer solution is in contact with opposite sides of said impregnated filter membrane; after a measured period of time, the donor plate~and acceptor plate are separated, the concentration of sample in each buffer solution is determined and the rate of permeation is calculated.
In another embodiment of the invention, a high through-put permeability instrument such as the PSR4p instrument manufactured by pION Inc., Woburn, MA may be utilized. In this embodiment, a parallel artificial membrane assay (PAMPA) technique is employed using as artificial membrane a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
Buffer solutions suitable for use in the method of invention include any conventional buffer solution of about pH 6.0-8.0, preferably about pH 7.2-7.6 and more preferably about pH 7.4.
Accordingly, the method of the invention demonstrates higher predictability for blood-brain barrier permeability with higher through-put capacity, lower cost and without the sacrifice of living animals than those methods currently known in the art.
The present invention also provides a membrane composition which comprises a porous solid support impregnated with a mixture of brain polar lipid extract and dodecane. The mixture of brain polar lipid extract and dodecane suitable for use in the inventive composition may be about 10% wt/vol to 30o wt/vol, preferably about 15o wt/vol to 25o wt/vol, more preferably about 19% wt/vol to 21o wt/vol of brain polar lipid extract in dodecane.
A porous solid support suitable for use in the inventive composition includes any commonly used porous material such as that used in the 96-well filter plates, for example polyvinylideneflouride or an equivalent thereof, preferably polyvinylideneflouride.
Brain polar lipid extracts suitable for use in the composition of the invention may be those brain polar lipid extracts, either synthetic or natural, which can be found in the literature or which are commercially available such as porcine, ovine, bovine or the like, preferably porcine brain polar lipid extract.
The composition of the invention may be prepared by impregnating the porous solid support with a mixture of brain polar lipid extract and dodecane at a level of at least 4~,L/38mm2, preferably about 4~,L/38mmz, of said mixture per area of porous solid support.
For a more clear understanding of the invention, the following examples are set forth below. These examples are merely illustrative and are not understood to limit the scope or underlying principles of the invention in any way. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the following examples and the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
After a measured period of time, the concentration of said compound or mixture of compounds is determined for each buffer solution and the rate of diffusion is calculated.
In one embodiment of the invention, a 96-well plate filled with solutions of a known concentration of test sample in a buffer solution (donor) may be covered with a 96-well filter plate wherein the porous filter membrane is impregnated with a mixture of brain polar lipid extract and dodecane and the wells are filled with a buffer solution containing 0% concentration of test sample (acceptor) such that the surface of each buffer solution is in contact with opposite sides of said impregnated filter membrane; after a measured period of time, the donor plate~and acceptor plate are separated, the concentration of sample in each buffer solution is determined and the rate of permeation is calculated.
In another embodiment of the invention, a high through-put permeability instrument such as the PSR4p instrument manufactured by pION Inc., Woburn, MA may be utilized. In this embodiment, a parallel artificial membrane assay (PAMPA) technique is employed using as artificial membrane a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
Buffer solutions suitable for use in the method of invention include any conventional buffer solution of about pH 6.0-8.0, preferably about pH 7.2-7.6 and more preferably about pH 7.4.
Accordingly, the method of the invention demonstrates higher predictability for blood-brain barrier permeability with higher through-put capacity, lower cost and without the sacrifice of living animals than those methods currently known in the art.
The present invention also provides a membrane composition which comprises a porous solid support impregnated with a mixture of brain polar lipid extract and dodecane. The mixture of brain polar lipid extract and dodecane suitable for use in the inventive composition may be about 10% wt/vol to 30o wt/vol, preferably about 15o wt/vol to 25o wt/vol, more preferably about 19% wt/vol to 21o wt/vol of brain polar lipid extract in dodecane.
A porous solid support suitable for use in the inventive composition includes any commonly used porous material such as that used in the 96-well filter plates, for example polyvinylideneflouride or an equivalent thereof, preferably polyvinylideneflouride.
Brain polar lipid extracts suitable for use in the composition of the invention may be those brain polar lipid extracts, either synthetic or natural, which can be found in the literature or which are commercially available such as porcine, ovine, bovine or the like, preferably porcine brain polar lipid extract.
The composition of the invention may be prepared by impregnating the porous solid support with a mixture of brain polar lipid extract and dodecane at a level of at least 4~,L/38mm2, preferably about 4~,L/38mmz, of said mixture per area of porous solid support.
For a more clear understanding of the invention, the following examples are set forth below. These examples are merely illustrative and are not understood to limit the scope or underlying principles of the invention in any way. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the following examples and the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
Comparative Evaluation of the Predictability for Blood Brain Barrier Permeability of the Inventive Method Using Known Compounds In this evaluation, 30 literature compounds for which the blood-brain barrier permeability is known (P.
Crivari, et al, Journal of Medicinal Chemistry, 2000, 43, 2204-2216) are each dissolved in DMSO at a Concentration of 5 mg/mL to give a stock solution for each compound. A
100 ~.L volume of each stock solution is placed into one well of a 96-well plate, and the well plate is placed in a PSR4p permeability analyzer manufactured by pION, Inc., Woburn, MA. A 10 ~,L volume of stock solution is robotically added to a deep 96-well plate containing 2.0 mL of pH 7.4 buffer solution. The resultant mixture is mechanically stirred to form the donor solution. A 200 ~.L volume of each donor solution is placed robotically into 3 wells of a 96-well plate to afford the donor plate. A vial containing 20 mg of porcine polar brain lipid extract manufactured by Avanti Polar Lipids, InC., Alabaster, AL, dissolved in 1 mL of dodeCane is placed in the reservoir of the PSR4p instrument. A 4 ~.L volume of this brain lipid solution is placed on the filter surface of each well of a 96-well microtiter filter well plate manufactured by Millipore Corp., Bedford, MA, wherein the the filter is a porous (0.45 ~,m) polyvinylidenefluoride material approximately 104 ~,m in thickness. The microtiter plate is then manually placed on an orbital shaker for 1 minute to yield a 96-well microtiter plate having a filter membrane permeated with a 20o wt/vol solution of porcine polar brain lipid extract in dodecane. A 200 ~.L volume of pH 7.4 buffer is robotically inserted into the wells of the thus-prepared.
microtiter 96-well filter plate to give a receptor plate, this receptor plate is placed on the donor plate to form a sandwich and allowed to stand at ambient temperature for 18 h.
A plate washer manufactured by Tecan, Hombrechin-tikon, Switzerland is then used to prepare a UV
transparent 96-well plate (W plate). The receptor plate is removed from the sandwich, a 150 ~.L volume of the receptor solution is robotically placed in the W plate, and the W absorption at 190-500 nm of each receptor well is recorded. The UV plate is then replaced in the plate washer, washed again and a 150 ~.L volume of the donor solution is robotically placed in the UV plate and the UV
absorption at 190-500 nm of each donor well is recorded.
The rate of passive diffusion is measured as linear velocity of permeation (Pe). The Pe is calculated for each compound using version V1.4 of the PSR4p software from pION Inc. Two standards, verapamil and theophylline, are used for each microtiter plate. BBB
permeability is designated as CNS+ for Pe values >4 x 10-6 cm/sec and as CNS- for Pe values <2 x 10-6 cm/sec. The data are averaged and the results are shown in Table I.
Table I
Test Pe CNS
Comt~ouad ( 10-scm/ s Eval Known2 ) Alprazolam 5.44 + +
Caffeine 1.30 - +
Chlorpromazine 6.36 + +
Clobazam 16.85 + +
Clonidine 5.31 + +
Desipramine 11.89 + +
_g_ Table I (cont'd) Test Pe CNS
Compound ( 10-scm/ Knownz s ) Eval Diazepam 16.41 + +
beta-Estradiol 11.61 + +
Imipramine 13.12 + +
Oxazepam 10.12 + +
Progesterone 9.28 + +
Promazine 8.84 + +
Testosterone 16.75 + +
Thiopental 18.13 + +
Aldosterone 1.19 - -Astemizolel 10.66 + -Atenolol 0.84 - -Hydrocortisone 1.99 - -Dopamine 0.16 - -Enoxin 0.90 - -Isoxicam 0.25 - -Lomefloxacin 1.19 - -Loperamide 0.00 - -Corticosteronel 5.13 + -Norfloxacin 0.14 - -Ofloxacin 0.80 - -Piroxicam 2.53 - -Terfenadine 0.00 - -Tenoxicam 0.14 - -Cimetidine 0.00 - -1 These compounds were involved in active processes, i.e., carrier mediated transport(caffeine), Pgp efflux (corticosterone) and rapidmetabolism (astemizole).
2 Crivori, P., et al., Journal of Medicinal Chemistry, 2000, 43, 2204-2216.
As can be seen by the data on Table I, the inventive method demonstrates 90% accuracy for all 30 test compounds including active transport processes. For passive diffusion, the inventive method demonstrates 1000 accuracy.
Comparative Evaluation of the Predictability for Blood Brain Barrier Permeability of the Inventive Method Using Experimental Compounds Using essentially the same procedure described in Example 1 and substituting experimental compounds obtained from three separate CNS projects, the Pe values are determined and compared to the blood-brain barrier permeability as determined by standard rat brain assay methodology or biological endpoints from in vivo studies.
The results are shown in Table II.
Table II
Test Pe CNS CNS
Com~aound ( 10-scm/ s Eval In vivo ) A 6.52 + +
B 6.07 + +
C 18.99 + +
D 11.61 + +
E 9.~8 + +
F 10.62 + +
G 15.11 + +
H 5.20 + +
I 13.75 + +
0.40 - -Table II, Contd Test Pe CNS CNS
Compound ( 10-scm/ s ) Eval . In vivo K 0.13 - -L 0.05 - -M 0.03 - -N 0.08 - -As can be seen from the data on Table II, the inventive method demonstrates 100% accuracy.
Crivari, et al, Journal of Medicinal Chemistry, 2000, 43, 2204-2216) are each dissolved in DMSO at a Concentration of 5 mg/mL to give a stock solution for each compound. A
100 ~.L volume of each stock solution is placed into one well of a 96-well plate, and the well plate is placed in a PSR4p permeability analyzer manufactured by pION, Inc., Woburn, MA. A 10 ~,L volume of stock solution is robotically added to a deep 96-well plate containing 2.0 mL of pH 7.4 buffer solution. The resultant mixture is mechanically stirred to form the donor solution. A 200 ~.L volume of each donor solution is placed robotically into 3 wells of a 96-well plate to afford the donor plate. A vial containing 20 mg of porcine polar brain lipid extract manufactured by Avanti Polar Lipids, InC., Alabaster, AL, dissolved in 1 mL of dodeCane is placed in the reservoir of the PSR4p instrument. A 4 ~.L volume of this brain lipid solution is placed on the filter surface of each well of a 96-well microtiter filter well plate manufactured by Millipore Corp., Bedford, MA, wherein the the filter is a porous (0.45 ~,m) polyvinylidenefluoride material approximately 104 ~,m in thickness. The microtiter plate is then manually placed on an orbital shaker for 1 minute to yield a 96-well microtiter plate having a filter membrane permeated with a 20o wt/vol solution of porcine polar brain lipid extract in dodecane. A 200 ~.L volume of pH 7.4 buffer is robotically inserted into the wells of the thus-prepared.
microtiter 96-well filter plate to give a receptor plate, this receptor plate is placed on the donor plate to form a sandwich and allowed to stand at ambient temperature for 18 h.
A plate washer manufactured by Tecan, Hombrechin-tikon, Switzerland is then used to prepare a UV
transparent 96-well plate (W plate). The receptor plate is removed from the sandwich, a 150 ~.L volume of the receptor solution is robotically placed in the W plate, and the W absorption at 190-500 nm of each receptor well is recorded. The UV plate is then replaced in the plate washer, washed again and a 150 ~.L volume of the donor solution is robotically placed in the UV plate and the UV
absorption at 190-500 nm of each donor well is recorded.
The rate of passive diffusion is measured as linear velocity of permeation (Pe). The Pe is calculated for each compound using version V1.4 of the PSR4p software from pION Inc. Two standards, verapamil and theophylline, are used for each microtiter plate. BBB
permeability is designated as CNS+ for Pe values >4 x 10-6 cm/sec and as CNS- for Pe values <2 x 10-6 cm/sec. The data are averaged and the results are shown in Table I.
Table I
Test Pe CNS
Comt~ouad ( 10-scm/ s Eval Known2 ) Alprazolam 5.44 + +
Caffeine 1.30 - +
Chlorpromazine 6.36 + +
Clobazam 16.85 + +
Clonidine 5.31 + +
Desipramine 11.89 + +
_g_ Table I (cont'd) Test Pe CNS
Compound ( 10-scm/ Knownz s ) Eval Diazepam 16.41 + +
beta-Estradiol 11.61 + +
Imipramine 13.12 + +
Oxazepam 10.12 + +
Progesterone 9.28 + +
Promazine 8.84 + +
Testosterone 16.75 + +
Thiopental 18.13 + +
Aldosterone 1.19 - -Astemizolel 10.66 + -Atenolol 0.84 - -Hydrocortisone 1.99 - -Dopamine 0.16 - -Enoxin 0.90 - -Isoxicam 0.25 - -Lomefloxacin 1.19 - -Loperamide 0.00 - -Corticosteronel 5.13 + -Norfloxacin 0.14 - -Ofloxacin 0.80 - -Piroxicam 2.53 - -Terfenadine 0.00 - -Tenoxicam 0.14 - -Cimetidine 0.00 - -1 These compounds were involved in active processes, i.e., carrier mediated transport(caffeine), Pgp efflux (corticosterone) and rapidmetabolism (astemizole).
2 Crivori, P., et al., Journal of Medicinal Chemistry, 2000, 43, 2204-2216.
As can be seen by the data on Table I, the inventive method demonstrates 90% accuracy for all 30 test compounds including active transport processes. For passive diffusion, the inventive method demonstrates 1000 accuracy.
Comparative Evaluation of the Predictability for Blood Brain Barrier Permeability of the Inventive Method Using Experimental Compounds Using essentially the same procedure described in Example 1 and substituting experimental compounds obtained from three separate CNS projects, the Pe values are determined and compared to the blood-brain barrier permeability as determined by standard rat brain assay methodology or biological endpoints from in vivo studies.
The results are shown in Table II.
Table II
Test Pe CNS CNS
Com~aound ( 10-scm/ s Eval In vivo ) A 6.52 + +
B 6.07 + +
C 18.99 + +
D 11.61 + +
E 9.~8 + +
F 10.62 + +
G 15.11 + +
H 5.20 + +
I 13.75 + +
0.40 - -Table II, Contd Test Pe CNS CNS
Compound ( 10-scm/ s ) Eval . In vivo K 0.13 - -L 0.05 - -M 0.03 - -N 0.08 - -As can be seen from the data on Table II, the inventive method demonstrates 100% accuracy.
Claims (12)
1. A method for the determination of the ability of a compound or mixture of compounds to permeate the blood-brain barrier which comprises measuring the rate said compound or mixture of compounds passively diffuses through a porous filter membrane impregnated with a mixture of brain polar lipid extract and dodecane.
2. The method according to Claim 1 wherein said extract is porcine brain polar lipid extract.
3. The method according to Claim 1 or 2 wherein said mixture is about 20% wt/vol of brain polar lipid extract in dodecane.
4. The method according to any one of Claims 1 to 3 wherein said impregnated membrane has a thickness of about 100 µm to 150 µm.
5. The method according to any one of Claims 1 to 4 wherein said filter membrane has a pore size of about 0.45 µm.
6. The method according to any one of Claims 1 to wherein said filter membrane is a polyvinylidenefluoride filter membrane.
7. The method according to any one of Claims 1 to 6 wherein said membrane is impregnated with about 4 µL of a mixture of brain polar lipid extract and dodecane per 38 mm2 of membrane.
8. A membrane composition which comprises a porous solid support impregnated with a mixture of brain polar lipid extract and dodecane.
9. The composition according to Claim 8 wherein said extract is porcine brain polar lipid extract.
10. The composition according to Claim 8 or 9 wherein said mixture is about 20% wt/vol brain polar lipid extract is dodecane.
11. The composition according to any one of Claims 8 to 10 wherein the porous solid support is a polyvinylidenefluoride filter membrane.
12. The composition according to any one of Claims 8 to 11 wherein said filter membrane is impregnated with at least 4 µL of a 20% wt/vol mixture of brain polar lipid extract in dodecane per 38 mm2 of said membrane.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30208501P | 2001-06-29 | 2001-06-29 | |
| US60/302,085 | 2001-06-29 | ||
| PCT/US2002/019736 WO2003003007A2 (en) | 2001-06-29 | 2002-06-20 | Methods and compositions useful for the prediction of blood-brain barrier permeation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2448746A1 true CA2448746A1 (en) | 2003-01-09 |
Family
ID=23166189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002448746A Abandoned CA2448746A1 (en) | 2001-06-29 | 2002-06-20 | Methods and compositions useful for the prediction of blood-brain barrier permeation |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1399539A2 (en) |
| JP (1) | JP2005501230A (en) |
| AR (1) | AR036121A1 (en) |
| AU (1) | AU2002315398A1 (en) |
| BR (1) | BR0210697A (en) |
| CA (1) | CA2448746A1 (en) |
| MX (1) | MXPA03011439A (en) |
| WO (1) | WO2003003007A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003065037A2 (en) | 2002-01-31 | 2003-08-07 | Pion, Inc. | Method and apparatus for measuring membrane permeability |
| US8986781B2 (en) * | 2005-10-27 | 2015-03-24 | Corning Incorporated | Immobilized multi-layer artificial membrane for permeability measurements (PAMPA) |
| DE102008007673A1 (en) * | 2008-01-25 | 2009-07-30 | Nimbus Biotechnologie Gmbh | Determination of the permeability of substances through the blood-brain barrier |
| IL307373A (en) | 2017-02-17 | 2023-11-01 | Denali Therapeutics Inc | Engineered Transferrin Receptor Binding Polypeptides |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260210A (en) * | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
-
2002
- 2002-06-20 BR BR0210697-3A patent/BR0210697A/en not_active Application Discontinuation
- 2002-06-20 EP EP02742248A patent/EP1399539A2/en not_active Withdrawn
- 2002-06-20 WO PCT/US2002/019736 patent/WO2003003007A2/en not_active Application Discontinuation
- 2002-06-20 AU AU2002315398A patent/AU2002315398A1/en not_active Abandoned
- 2002-06-20 CA CA002448746A patent/CA2448746A1/en not_active Abandoned
- 2002-06-20 MX MXPA03011439A patent/MXPA03011439A/en unknown
- 2002-06-20 JP JP2003509140A patent/JP2005501230A/en active Pending
- 2002-06-28 AR ARP020102434 patent/AR036121A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1399539A2 (en) | 2004-03-24 |
| WO2003003007A3 (en) | 2003-05-22 |
| AU2002315398A1 (en) | 2003-03-03 |
| WO2003003007A2 (en) | 2003-01-09 |
| MXPA03011439A (en) | 2004-04-05 |
| JP2005501230A (en) | 2005-01-13 |
| AR036121A1 (en) | 2004-08-11 |
| BR0210697A (en) | 2004-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2183594B1 (en) | Bilayers | |
| AU666821B2 (en) | Analyte detection device and process | |
| CA2024064A1 (en) | Blood separation and analyte detection techniques | |
| WO2002006828A3 (en) | Hemoglobin sensor | |
| DE60207196T2 (en) | Method and apparatus for quantification of high density lipoprotein cholesterol | |
| CA2448746A1 (en) | Methods and compositions useful for the prediction of blood-brain barrier permeation | |
| EP0274911A1 (en) | Diagnostic device, method for making, and method for using | |
| AU2015312013B2 (en) | Methods relating to testing for lysosomal storage disorders | |
| US7060428B2 (en) | Methods and compositions useful for the prediction of blood-brain barrier permeation | |
| PT2282206E (en) | Method and apparatus for assaying several analytes simultaneously with an internal control | |
| Zheng et al. | A magnetically active microfluidic device for chemiluminescence bioassays | |
| EP2564196B1 (en) | Microfluidic system with sample pre-treatment | |
| US20140329229A1 (en) | Absorbent dried biofluid collection substrates | |
| AU670882B2 (en) | Analyte detection device and process | |
| EP3489681B1 (en) | Method for observing dynamics of sweat glands | |
| US20210096120A1 (en) | Method for determining release rates of active principle ingredients from at least one semisolid form | |
| EP2637021A1 (en) | Method and device for detecting analytes | |
| CN1736532A (en) | Hollow membraned tubular micro-extraction analyzer and application method thereof | |
| Medyantseva et al. | An amperometric monoamine oxidase biosensor for determining some antidepressants | |
| Cohen | A simple, rapid and highly sensitive method of separation and quantification of uric acid, hypoxanthine, and xanthine by HPLC | |
| Toneby | Detection of 5-hydroxytryptamine in developing sea urchin embryos | |
| Wilson et al. | Direct Electromembrane Extraction based Mass Spectrometry: A Tool for Studying Drug Metabolism Properties of Liver Organoids | |
| Hammond et al. | Isolation and characterization of renal cortical membranes using an aqueous two-phase partition technique | |
| CN1791669A (en) | Method and compositions useful for the prediction of blood-brain barrier permeation | |
| ES2206262T3 (en) | PROCEDURE FOR THE QUANTITATIVE DETERMINATION OF ALCALOIDS, SUCH AS COCAINE, IN A SOLID SAMPLE, AND REAGENT FOR USE IN THIS PROCEDURE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |